[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Outcomes'10\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":83},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100612375","nutritional-management-of-the-patient-with-type-2-diabetes-at-nutritional-risk-or-with-malnutrition-in-clinical-practice-100612375",false,"NCT07252765","Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice","Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice. STARLIGHT Study","STARLIGHT","Inclusion Criteria:\n\n* Adult patients diagnosed with type 2 diabetes (T2D) or drug-induced diabetes\n* Patients at nutritional risk according to MUST or presenting malnutrition according to GLIM criteria.\n* Patients requiring a diabetes-specific oral nutritional supplement (ONS) that is high-calorie, high-protein, and contains soluble fiber in real-world clinical practice, and who have been prescribed such a supplement within the previous 7 days.\n* Patients able to provide informed consent and complete the study questionnaires.\n\nExclusion Criteria:\n\n* Patients participating in other studies or clinical trials related to malnutrition, or who, in the investigator's opinion, may alter the course of the study.\n* Patients currently receiving or expected to receive other types of nutritional interventions involving supplements (oral or otherwise) or non-conventional feeding methods (e.g., feeding tubes).\n* Patients with a history of metabolic\u002Fendocrine diseases (other than diabetes) or any other condition causing liver or kidney failure, defined as ALT \\> 3x ULN or eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m², and according to the investigator's judgment.\n* Patients expected to undergo any surgical intervention or require hospitalization due to a condition unrelated to the study during the study period.\n* Patients with other conditions that, in the investigator's opinion, may interfere with adherence to the intervention or with study procedures.","ALL","18 Years",{"count":20,"type":21},334,"ESTIMATED","OBSERVATIONAL","The objective of this observational study is to characterize the patient profile and nutritional treatment patterns of individuals with type 2 diabetes (T2D) or drug-induced diabetes who present with malnutrition, or are at risk of it, and who are prescribed a diabetes-specific oral nutritional supplement (ONS) that is high in calories and protein and contains soluble fiber.\n\nParticipants will complete a series of questionnaires during visits 1 and 3.",[25,26,27,28],"Type 2 Diabetes Mellitus (T2DM)","Malnutrition","Malnourishment","Drug-Induced Diabetes",[30,31,32,33,34,35,27,26,36],"Metabolic control","Disease - realted malnutrition","Diabetes-specific formula","T2D","Oral nutritional supplementation","Type 2 Diabetes Mellitus","Drug-induced diabetes","RECRUITING","2026-01-26",{"date":40,"type":41},"2026-01-28","ACTUAL",{"date":43,"type":41},"2025-11-20",{"date":45,"type":21},"2026-10",{"name":47,"class":48},"Outcomes'10","NETWORK",12,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":57,"enrollmentInfo":58,"targetDuration":60,"studyType":22,"phases":4,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},"100619284","smash-study-to-evaluate-the-clinical-efficacy-of-an-extensively-hydrolysed-infant-formula-with-synbiotics-and-a-human-milk-oligosaccharide-hmo-in-infants-with-cows-milk-protein-allergy-cmpa-100619284","NCT07342621","SMASH: Study to Evaluate the Clinical Efficacy of an Extensively Hydrolysed Infant Formula With Synbiotics and a Human Milk Oligosaccharide (HMO) in Infants With Cow's Milk Protein Allergy (CMPA)","SMASH","Inclusion Criteria:\n\n* Infants under 10 months of age at study start (Visit 1).\n* Suspected or recently confirmed cow's milk protein allergy (CMPA), as determined by the investigator.\n* Already formula-fed, or parents\u002Flegal guardians have decided to initiate formula feeding.\n* Inclusion in the study coincides with the first prescription of a hypoallergenic formula.\n* Written informed consent obtained from parents or legal guardians in accordance with local regulations.\n\nExclusion Criteria:\n\n* Infants with functional gastrointestinal symptoms in whom atopy or food allergy is not suspected.\n* Infants who have previously used an extensively hydrolyzed formula (EHF), an amino acid-based formula (AAF), a rice hydrolysate formula, or a soy-based formula.\n* Infants who have previously used a partially hydrolyzed formula for the prevention of cow's milk protein allergy (CMPA).\n* Infants for whom an amino acid-based formula (AAF) is more appropriate as first-line management, including severe forms of CMPA.\n* Contraindications to the use of synbiotics (e.g., preterm infants \\\u003C40 weeks of corrected gestational age at study start, immunodeficiency, short bowel syndrome, parenteral nutrition, post-pyloric feeding, central venous catheter, oncology treatment, or graft-versus-host disease).\n* Any other condition, as assessed by the investigator, that contraindicates the use of an extensively hydrolyzed formula.\n* Any other circumstance, as assessed by the investigator, indicating that the parents or legal guardians are not capable of complying with the study procedures.","10 Months",{"count":59,"type":21},41,"4 Weeks","Cow's milk protein allergy (CMPA) is one of the most common food allergies in infants, with an estimated prevalence between 2% and 5%. The number of diagnosed cases has increased in recent years, with clinical manifestations involving the gastrointestinal tract, respiratory system, skin, or systemic reactions. Dietary elimination of cow's milk protein remains the mainstay of treatment, using extensively hydrolyzed formulas (EHF) or amino acid-based formulas (AAF), depending on the severity of the allergy.\n\nThis study aims to evaluate the clinical effect, as reported by physicians, of an extensively hydrolyzed whey-based formula (Almirón Pepti Syneo®) containing a symbiotic mixture (scGOS\u002FlcFOS 9:1 and Bifidobacterium breve M-16V), the human milk oligosaccharide 2'-fucosyllactose (2'-FL), and a reduced amount of purified lactose, in infants with suspected or confirmed CMPA in a real-world clinical practice setting.\n\nThis is a prospective, longitudinal, open-label, single-arm, multicenter study including approximately 41 infants under 10 months of age at several primary care centers and one hospital in Valencia, Spain. Each participant will be followed for four weeks. A subgroup of participants will also provide stool samples to explore the effect of the study formula on gut microbiota composition.",[63,64,65,66],"Cow's Milk Protein Allergy (CMPA)","Food Hypersensitivity","Infant Nutrition Disorders","Gut Microbiota",[68,69,70,71,72,73],"Extensively Hydrolyzed Formula","Synbiotics","Cow's Milk Protein Allergy","Real World Evidence","Microbiota","Gastrointestinal Symptoms","2026-01-05",{"date":76,"type":41},"2026-01-15",{"date":78,"type":41},"2025-02-07",{"date":80,"type":21},"2026-04",{"name":47,"class":48},13,""]